Stifel Lifts MBX Biosciences Price Target to $84 From $70
Stifel kept its Buy rating on MBX Biosciences and raised the stock’s price target to $84 from $70, according to Benzinga ratings actions.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires, citing ratings actions from Benzinga, reported that Stifel maintained its Buy rating on MBX Biosciences.
The firm also raised its price target to $84 per share from $70. The information was published at 11:29 GMT.
why it matters
Keeping the Buy rating while raising the price target signals a changed assessment by Stifel and may be considered by market participants evaluating MBX Biosciences shares.
instruments
sources
- MBX Biosciences Price Target Raised to $84.00/Share From $70.00 by Stifel — Dow Jones Newswires, 12 October 2026 at 11:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗